Peter Jenkins

2.0k total citations · 1 hit paper
31 papers, 1.3k citations indexed

About

Peter Jenkins is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Peter Jenkins has authored 31 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Peter Jenkins's work include Bladder and Urothelial Cancer Treatments (10 papers), Advanced Radiotherapy Techniques (6 papers) and Urinary and Genital Oncology Studies (6 papers). Peter Jenkins is often cited by papers focused on Bladder and Urothelial Cancer Treatments (10 papers), Advanced Radiotherapy Techniques (6 papers) and Urinary and Genital Oncology Studies (6 papers). Peter Jenkins collaborates with scholars based in United Kingdom, Belgium and United States. Peter Jenkins's co-authors include Emma Hall, Nicholas D. James, Jean Tremlett, Robert Huddart, Syed A. Hussain, Christine Rawlings, Rebecca Lewis, Malcolm Crundwell, Carey Hendron and Rachel Waters and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Peter Jenkins

29 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

2012 617 citations Nicholas D. James, Syed A. Hussain et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Jenkins United Kingdom	17	777	386	355	318	200	31	1.3k
Richard P. Meijer Netherlands	21	1.1k 1.4×	396 1.0×	565 1.6×	349 1.1×	110 0.6×	96	1.7k
Lorne D. Sullivan Canada	19	584 0.8×	415 1.1×	1.4k 3.9×	292 0.9×	107 0.5×	48	2.1k
Hedy Mameghan Australia	20	415 0.5×	254 0.7×	602 1.7×	72 0.2×	192 1.0×	54	1.2k
Avi Stein Israel	23	423 0.5×	209 0.5×	721 2.0×	153 0.5×	81 0.4×	73	1.4k
Stefan Tritschler Germany	24	1.0k 1.3×	212 0.5×	601 1.7×	473 1.5×	322 1.6×	88	1.6k
Bruce Sizer United Kingdom	13	732 0.9×	469 1.2×	247 0.7×	224 0.7×	131 0.7×	21	1.1k
A. Garbeglio Italy	13	740 1.0×	211 0.5×	451 1.3×	279 0.9×	158 0.8×	27	1.2k
Friedhelm Wawroschek Germany	22	563 0.7×	257 0.7×	1.4k 3.8×	89 0.3×	309 1.5×	90	1.9k
Michael J. Wehle United States	14	432 0.6×	96 0.2×	619 1.7×	231 0.7×	62 0.3×	31	979
R. McMenemin United Kingdom	15	275 0.4×	513 1.3×	676 1.9×	74 0.2×	212 1.1×	42	1.2k

Countries citing papers authored by Peter Jenkins

Since Specialization

Citations

This map shows the geographic impact of Peter Jenkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Jenkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Jenkins more than expected).

Fields of papers citing papers by Peter Jenkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Jenkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Jenkins. The network helps show where Peter Jenkins may publish in the future.

Co-authorship network of co-authors of Peter Jenkins

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Jenkins. A scholar is included among the top collaborators of Peter Jenkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Jenkins. Peter Jenkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hall, Emma, Syed A. Hussain, Núria Porta, et al.. (2022). Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. European Urology. 82(3). 273–279. 59 indexed citations

Hussain, Syed A., Núria Porta, Emma Hall, et al.. (2020). Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. European Urology. 79(2). 307–315. 19 indexed citations

Hussain, Syed A., Emma Hall, Núria Porta, et al.. (2017). Outcome of BC2001 patients (CRUK/01/004) who received neoadjuvant chemotherapy prior to randomization to chemo-radiotherapy (cRT) versus radiotherapy (RT).. Journal of Clinical Oncology. 35(6_suppl). 298–298. 2 indexed citations

Molife, L. Rhoda, Aurelius Omlin, Robert J. Jones, et al.. (2014). Randomized Phase II Trial of Nintedanib, Afatinib and Sequential Combination in Castration-Resistant Prostate Cancer. Future Oncology. 10(2). 219–231. 30 indexed citations

Huddart, Robert, Emma Hall, Syed A. Hussain, et al.. (2013). Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004). International Journal of Radiation Oncology*Biology*Physics. 87(2). 261–269. 97 indexed citations

James, Nicholas D., Syed A. Hussain, Emma Hall, et al.. (2012). Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. New England Journal of Medicine. 366(16). 1477–1488. 617 indexed citations breakdown →

Jenkins, Peter, Jessica Scaife, & Sylvie Freeman. (2011). Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Annals of Oncology. 23(7). 1766–1771. 31 indexed citations

Jenkins, Peter, et al.. (2011). Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma. European Journal of Cancer. 47(14). 2143–2149. 22 indexed citations

Jenkins, Peter, et al.. (2011). Computed Tomography Appearance of Early Radiation Injury to the Lung: Correlation With Clinical and Dosimetric Factors. International Journal of Radiation Oncology*Biology*Physics. 81(1). 97–103. 50 indexed citations

10.

Jenkins, Peter, et al.. (2011). An Improved Model for Predicting Radiation Pneumonitis Incorporating Clinical and Dosimetric Variables. International Journal of Radiation Oncology*Biology*Physics. 80(4). 1023–1029. 53 indexed citations

11.

James, Nicholas D., Syed A. Hussain, Emma Hall, et al.. (2010). Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004). International Journal of Radiation Oncology*Biology*Physics. 78(3). S2–S3. 11 indexed citations

12.

James, Nicholas D., Syed A. Hussain, Emma Hall, et al.. (2010). Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004).. Journal of Clinical Oncology. 28(15_suppl). 4517–4517. 16 indexed citations

13.

Jenkins, Peter, et al.. (2009). A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer. Radiotherapy and Oncology. 93(3). 396–401. 10 indexed citations

14.

Jenkins, Peter, et al.. (2009). Defining the Clinical Target Volume for Bladder Cancer Radiotherapy Treatment Planning. International Journal of Radiation Oncology*Biology*Physics. 75(5). 1379–1384. 16 indexed citations

15.

Jenkins, Peter & Sylvie Freeman. (2008). Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Annals of Oncology. 20(1). 34–40. 49 indexed citations

16.

Jenkins, Peter, et al.. (2007). Shrinkage of Locally Advanced Non–Small-Cell Lung Cancers in Response to Induction Chemotherapy: Implications for Radiotherapy Treatment Planning. International Journal of Radiation Oncology*Biology*Physics. 69(4). 993–1000. 10 indexed citations

17.

Jenkins, Peter, et al.. (2006). Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. European Journal of Cancer. 43(3). 544–548. 28 indexed citations

18.

Jenkins, Peter, et al.. (2005). Analysis of the movement of calcified lymph nodes during breathing. International Journal of Radiation Oncology*Biology*Physics. 61(2). 329–334. 18 indexed citations

19.

Jenkins, Peter, et al.. (2003). Radiation pneumonitis following treatment of non–small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART). International Journal of Radiation Oncology*Biology*Physics. 56(2). 360–366. 49 indexed citations

20.

Jenkins, Peter, et al.. (1997). The role of vaginal estrogen in the treatment of urogenital dysfunction in postmenopausal women.. PubMed. 17(3). 92–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact